Literature DB >> 14652367

Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice.

Joshua D Lambert1, Mao-Jung Lee, Hong Lu, Xiaofeng Meng, Jihyeung Ju Jungil Hong, Darren N Seril, Marc G Sturgill, Chung S Yang.   

Abstract

Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea (Camellia sinensis), has shown cancer preventive activity in animal models. The bioavailability of EGCG in the most commonly used animal species, mice, is poorly understood. Moreover, the pharmacokinetic parameters of EGCG have not been reported previously in mice. Here we report that after administration of EGCG intravenously at 21.8 micro mol/kg or intragastrically at 163.8 micro mol/kg, the peak plasma levels of EGCG in male CF-1 mice were 2.7 +/- 0.7 and 0.28 +/- 0.08 micro mol/L, respectively. EGCG was present mainly (50-90%) as the glucuronide. The plasma bioavailability of EGCG after intragastric administration was higher than previously reported in rats (26.5 +/- 7.5% vs. 1.6 +/- 0.6%). The conjugated EGCG displayed a shorter t(1/2) (82.8-211.5 vs 804.9-1102.3 min) than unconjugated EGCG (P < 0.01, Student's t test). EGCG was present in the unconjugated form in the lung, prostate and other tissues at levels of 0.31-3.56 nmol/g after intravenous administration. Although intragastric administration resulted in lower levels in most tissues compared with intravenous administration (e.g., 0.006 +/- 0.004 vs. 2.66 +/- 1.0 nmol/g in the lung), the levels in the small intestine and colon were high at 45.2 +/- 13.5 and 7.86 +/- 2.4 nmol/g, respectively. This is the first report of the pharmacokinetic parameters of EGCG in mice. Such information provides a basis for understanding the bioavailability of EGCG in mice and should aid in understanding the cancer preventive activity of EGCG.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652367     DOI: 10.1093/jn/133.12.4172

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  73 in total

1.  Effect of green tea powder (Camellia sinensis L. cv. Benifuuki) particle size on O-methylated EGCG absorption in rats; The Kakegawa Study.

Authors:  Mari Maeda-Yamamoto; Kaori Ema; Yoshiko Tokuda; Manami Monobe; Hirofumi Tachibana; Yoichi Sameshima; Shinichi Kuriyama
Journal:  Cytotechnology       Date:  2011-01-05       Impact factor: 2.058

2.  Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells.

Authors:  Sujit Nair; Avantika Barve; Tin-Oo Khor; Guo-xiang Shen; Wen Lin; Jefferson Y Chan; Li Cai; Ah-Ng Kong
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 3.  The pharmokinetic limitations of antioxidant treatment for COPD.

Authors:  Robert Foronjy; Alison Wallace; Jeanine D'Armiento
Journal:  Pulm Pharmacol Ther       Date:  2007-10-23       Impact factor: 3.410

Review 4.  Tea and human health: biomedical functions of tea active components and current issues.

Authors:  Zong-mao Chen; Zhi Lin
Journal:  J Zhejiang Univ Sci B       Date:  2015-02       Impact factor: 3.066

5.  Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice.

Authors:  Joshua D Lambert; Mary J Kennett; Shengmin Sang; Kenneth R Reuhl; Jihyeung Ju; Chung S Yang
Journal:  Food Chem Toxicol       Date:  2009-10-31       Impact factor: 6.023

6.  Inhibition of starch digestion by the green tea polyphenol, (-)-epigallocatechin-3-gallate.

Authors:  Sarah C Forester; Yeyi Gu; Joshua D Lambert
Journal:  Mol Nutr Food Res       Date:  2012-10-05       Impact factor: 5.914

Review 7.  Epigenetic effects of green tea polyphenols in cancer.

Authors:  Susanne M Henning; Piwen Wang; Catherine L Carpenter; David Heber
Journal:  Epigenomics       Date:  2013-12       Impact factor: 4.778

8.  Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate.

Authors:  Daire O'Shea; John Law; Adrian Egli; Donna Douglas; Gary Lund; Sarah Forester; Joshua Lambert; Mansun Law; Dennis R Burton; D L J Tyrrell; Michael Houghton; Atul Humar; Norman Kneteman
Journal:  Liver Transpl       Date:  2016-01-29       Impact factor: 5.799

9.  Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.

Authors:  Adam Smith; Brian Giunta; Paula C Bickford; Michael Fountain; Jun Tan; R Douglas Shytle
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

Review 10.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.